CSLLY Stock - CSL Limited
Unlock GoAI Insights for CSLLY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $15.43B | $14.80B | $13.17B | $10.49B | $10.27B |
| Gross Profit | $7.95B | $7.56B | $6.71B | $5.66B | $5.74B |
| Gross Margin | 51.5% | 51.1% | 50.9% | 54.0% | 55.9% |
| Operating Income | $2.96B | $3.81B | $2.90B | $2.92B | $2.59B |
| Net Income | $3.00B | $2.64B | $2.19B | $2.25B | $1.78B |
| Net Margin | 19.5% | 17.9% | 16.7% | 21.5% | 17.4% |
| EPS | $3.10 | $2.74 | $2.28 | $3.32 | $2.63 |
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 10th 2022 | Credit Suisse | Upgrade | Outperform | - |
Earnings History & Surprises
CSLLYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 10, 2026 | — | — | — | — |
Q3 2025 | Aug 18, 2025 | — | — | — | — |
Q1 2025 | Feb 11, 2025 | — | $2.56 | — | — |
Q4 2024 | Oct 30, 2024 | — | $2.03 | — | — |
Q3 2024 | Aug 13, 2024 | — | $0.76 | — | — |
Q2 2024 | Apr 11, 2024 | — | $0.76 | — | — |
Q1 2024 | Feb 13, 2024 | — | $1.95 | — | — |
Q4 2023 | Dec 30, 2023 | — | $2.78 | — | — |
Q2 2023 | Jun 30, 2023 | — | $0.81 | — | — |
Q1 2023 | Mar 31, 2023 | — | $0.59 | — | — |
Q4 2022 | Dec 30, 2022 | — | $2.36 | — | — |
Q3 2022 | Sep 30, 2022 | — | $1.70 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.67 | — | — |
Q1 2022 | Mar 31, 2022 | — | $0.51 | — | — |
Q4 2021 | Dec 30, 2021 | — | $1.92 | — | — |
Q3 2021 | Sep 30, 2021 | — | $1.92 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.62 | — | — |
Q1 2021 | Mar 31, 2021 | — | $0.62 | — | — |
Q4 2020 | Dec 30, 2020 | — | $1.97 | — | — |
Q3 2020 | Sep 30, 2020 | — | $1.99 | — | — |
Frequently Asked Questions about CSLLY
What is CSLLY's current stock price?
What is the analyst price target for CSLLY?
What sector is CSL Limited in?
What is CSLLY's market cap?
Does CSLLY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CSLLY for comparison